Neuroscience

Neurophet Showcases ‘Brain Imaging AI Solutions’ at BIO USA, Accelerates Global Business Development Collaborations

Introduces key products including an integrated brain imaging analysis solution for Alzheimer's disease treatment decision-makingExpands partnering efforts with global pharmaceutical...

Nervonik Announces Completion of Groundbreaking First-in-Human Feasibility Study Demonstrating Nerve Sensing during Peripheral Nerve Stimulation in Multiple Anatomical Targets

LOS ANGELES, June 16, 2026 /PRNewswire/ -- Nervonik, a clinical-stage medical device company developing next-generation peripheral nerve stimulation (PNS) technologies,...

Nervonik Announces Completion of Groundbreaking First-in-Human Feasibility Study Demonstrating Nerve Sensing during Peripheral Nerve Stimulation in Multiple Anatomical Targets

LOS ANGELES, June 16, 2026 /PRNewswire/ -- Nervonik, a clinical-stage medical device company developing next-generation peripheral nerve stimulation (PNS) technologies,...

Tris Pharma to Present on Dual NOP/MOP Receptor Agonist in Pain Management and Substance Use Disorder at the College on Problems of Drug Dependence (CPDD) 88th Annual Scientific Meeting, 2026

Cebranopadol is an investigational, first-in-class dual-NMR agonist in development for acute and chronic pain as well as opioid use disorderFive...

CONNECTA Therapeutics Initiates Phase IIa Clinical Trial of CTH120, a First-in-Class Neuroplasticity Modulator, in Fragile X Syndrome

Builds on positive Phase I safety data and represents a key value-inflection milestone for the CompanyAdvances a potentially disease-modifying approach...

Frontiers in Neuroscience Accepts Review Article Synthesizing Evidence that Cervical nVNS Activates the Vagus Nerve Without Surgery

ROCKAWAY, N.J., June 09, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced...

BrainsWay Presents First SWIFT™ Accelerated Deep TMS 12-Month Durability Data at Clinical TMS Society Annual Meeting

Preliminary Data Analysis Reveals Over 80% Remission Rate One Year after Accelerated Deep TMS Treatment, with Decline in Severe Functional...

error: Content is protected !!